<DOC>
	<DOCNO>NCT00151385</DOCNO>
	<brief_summary>This investigation utilize systematic determination anti-FVIII antibody specificity PTPs ( &gt; 50 ED ) hemophilia A develop inhibitor response treatment FVIII product ( ) . A group patient hemophilia A , evidence current prior FVIII inhibitor include comparison . The objective study describe pattern antibody associate epitope study population .</brief_summary>
	<brief_title>Study Evaluating Inhibitor Specificity Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Â· Patients moderate severe congenital hemophilia A , current FVIII inhibitor , take least two different FVIII product lifetime . Patients inhibitor prior current inhibitor . Patients immune disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>